To determine if neurometabolic changes in the white matter (WM) of systemic lupus erythematosus (SLE) patients may predict the appearance of small hyperintense lesions on T2-weighted magnetic resonance imaging (MRI) inside the magnetic resonance spectroscopy (MRS) region of interest (ROI). We included 30 SLE patients and 23 controls. We performed single voxel proton MRS over the superior-posterior region of the corpus callosum. We measured signals from N-acetyl-compounds (NAA), choline (Cho) and creatine-phosphocreatin (Cr) and determined NAA/Cr and Cho/Cr ratios. After a minimum of 12 months, MRI and MRS were repeated in all patients and nine volunteers. Twenty patients had normal MRI and 10 patients had MRI hyperintense lesions in the MRS ROI at baseline. All patients had hyperintense lesions in the MRS ROI in follow-up MRIs. All SLE patients had increased Cho/Cr values at both MRS when compared with normal controls (P = 0.001). In addition, there was an increase in Cho/Cr values when patients' baseline and follow-up MRS were compared (P = 0.001). We observed a correlation between Cho/Cr ratios and number of WM lesions (r = 0.69; P = 0.001). Increased Cho/Cr in normal appearing WM may be indicative of future appearance of hyperintense T2-weighted MRI lesions in SLE patients. Lupus (2007) 16, 963—971.
Castellino G. , Govoni M., Padovan M., Colamussi P., Borrelli M., Trotta F.Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann Rheum Dis2005; 64: 1022—1027.
2.
Stimmler MM, Coletti PM, Quismorio FPMagnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum1993; 22: 335—349.
3.
McCune WJ , MacGuire A., Aisen A., Gebarski S.Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum1998; 31: 159—166.
4.
Bell CL, Partington C., Robbins M., Graziano F., Turski P., Kornguth S.Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers. Arthritis Rheum1991; 34: 432—441.
5.
Sibbitt WL Jr, Sibbitt RR, Griffey RH, Eckel C., Bankhurst ADMagnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis1989; 48: 1014—1022.
6.
Aisen AM, Gabrielsen TO, McCune WJMR imaging of systemic lupus erythematosus involving the brain. Am J Roentgenol1985; 144: 1027—1031.
7.
West SG, Woodruff E., Wener MH, Kotzin BLNeuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med1995; 99: 153—163.
8.
Karassa FB, Ioannidis JP, Boki KA et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med2000; 109: 628—634.
9.
Sanna G., Piga M., Terryberry JW et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus2000 ; 9: 573—583.
10.
Jennings JE, Sundgren PC, Attwood J., McCune J., Maly P.Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology2004 ; 46: 15—21.
11.
Colamussi P. , Giganti M., Cittanti C. et al. Brain single-photon emission tomography with 99mTc HMPAO in neuropsychiatric systemic lupus erythematosus: relations with EEG and MRI findings and clinical manifestations. Eur J Nucl Med1995; 22: 17—24.
12.
Nossent JC, Hovestadt DH, Schonfeld DHW, Swaak AJG.Single-photon emission computed tomography of the brain in the evaluation of cerebral lupus. Arthritis Rheum1991; 34: 1397—1403.
13.
Rubbert A., Marienhagen J., Pirner K. et al. Single photon emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum1993; 36: 1253—1262.
14.
Sibbitt WL, Sibbitt RRMagnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am1993; 19: 851—868.
15.
Castillo M. , Kwock L., Mukhery I.Clinical applications of proton MR spectroscopy . Am J Neuroradiol1996; 17: 1—15.
16.
Narayana PAMagnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging2005 ; 15: 46S—57S.
17.
Sibbitt WL Jr, Haseler LJ, Griffey RH, Hart BL, Sibbitt RR, Matwiyoff NAAnalysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy . Am J Neuroradiol1994; 15: 923—928.
18.
Handa R., Sahota P., Kumar M. et al. In vivo proton magnetic resonance spectroscopy (MRS) and single photon emission computerized tomography (SPECT) in systemic lupus erythematosus (SLE). Magn Reson Imaging2003; 21: 1033—1037.
19.
Lim MK, Suh CH, Kim HJ et al. Systemic lupus erythematosus: brain MR imaging and single-voxel hydrogen MR spectroscopy. Radiology2000; 217: 43—49.
20.
Axford JS, Howe FA, Heron C., Griffiths JRSensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus . Ann Rheum Dis2001; 60: 106—111.
21.
Peterson PL , Howe FA, Clark CA, Axford JSQuantitative magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus. Lupus2003; 12: 897—902.
22.
Appenzeller S., Li LM, Costallat LT, Cendes F.Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain2005; 128: 2933—2940.
23.
Tartaglia MC , Narayanan S., De Stefano N. et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol2002; 249: 1382—1390.
24.
Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271—1277.
25.
Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CHDerivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630—640.
26.
Harris EN, Gharavi AE, Patel SP, Hughes GREvaluation of the anticardiolipine antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol1987; 68: 215—222.
27.
Brandt JT, Triplett DA, Alving B., Scharrer I.Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost1995; 74: 1185—1190.
28.
ACRAd Hoc Committee on Neuropsychiatric Lupus. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum1999; 42: 599—608.
29.
Folstein MF , Folstein SE, Folstein PR `Mini mental state': a practical method for grading the cognitive state of patient for the clinician . J Psychiatr Res1975; 12: 189—198.
30.
Spranoel HZThe psychoeducational use and interpretation of the Wechsler adult intelligence scale—revised. Springfield: CC Thomas, 1992.
31.
Wechsler in Muistiasteikko, Suom. Anja Manner. Helsinki : Psykologien Kustannus, 1986.
32.
Delis DC, Kramer JH, Kaplan E. et al. California verbal learning test research edition manual. San Antonio, TX: The Psychological Corporation , 1987.
33.
Lezak MDNeuropsychological assessmentNY: Oxford University Press, 1995.
34.
Heaton RK, Chelune GJ, Talley JL et al. Wisconsin card sorting test manual, revised and expanded. Odessa: Psychological Assessment Resources, Inc., 1993.
35.
Beck AT, Beamesderfer A.Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiat1974; 7: 151—169.
36.
Beck AT, Rial WY, Rickels K.Short form of depression inventory: cross-validation. Psychol Rep1974; 34: 1184—1186.
37.
Herrmann C.International experiences with the hospital anxiety and depression scale—a review of validation data and clinical results. J Psychosom Res1997; 42: 17—41.
38.
Overall JE, Beller SAThe brief psychiatric rating scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol1984; 39: 187—193.
39.
Headache Classification Committee of the International Headache Society.Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia1988; 8: 1—96.
40.
Pajaron E., Lainez JM, Monzon MJ, Parra J., Peiro C., Sancho J.The validity of the classification criteria of the international headache society for migraine, tension headache and chronic tension headache. Neurologia1999; 14: 283—288.
41.
Bensenor IJ , Lotufo PA, Pereira AC et al. Validation of a questionnaire for the diagnosis of headache in an outpatient clinic at a university hospital. Arq Neuropsiquiatr1997 ; 55: 364—369.
42.
Appenzeller S., Costallat LTClinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia2004; 24: 1024—1030.
43.
Gladman DD, Urowitz MB, Kagal A., Hallett D.Accurately describing changes in disease activity in systemic lupus erythematosus . J Rheumatol2000; 27: 377—379.
44.
Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the systemic lupus international collaborating clinics/American college of rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum1997; 40: 809—813.
45.
Bottomley PASpatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci1987; 508: 333—348.
46.
Appenzeller S., Rondina JM, Li LM, Costallat LT, Cendes F.Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum2005; 52: 2783—2789.
47.
Sibbitt WL, Brooks WM, Haseler LJ et al. Spin-spin relaxation of brain tissues in systemic lupus erythematosus: method for increasing the sensitivity of magnetic resonance imaging for neuropsychiatric lupus. Arthritis Rheum1995; 38: 810—818.
48.
Rozell CL, Sibbitt WL, Brooks WMStructural and neurochemical markers of brain injury in the migraine diathesis of systemic lupus erythematosus. Cephalalgia1998; 18: 209—215.
49.
Sabet A., Sibbitt WL Jr, Stidley CA, Danska J., Brooks WMNeurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus . Stroke1998; 29: 2254—2260.
50.
Sibbitt WL Jr, Haseler LJ, Griffey RR, Friedman SD, Brooks WMNeurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. AJNR Am J Neuroradiol1997; 18: 1271—1277.
51.
Brooks WM, Sabet A., Sibbitt WL Jr et al. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J Rheumatol1997; 24: 2323—2329.
52.
Brooks WM, Jung RE, Ford CC, Greinel EJ, Sibbitt WL Jr.Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol1999; 26: 81—85.
53.
Sundgren PC , Jennings J., Attwood JT et al. MRI and 2D-CSI MR spectroscopy of the brain in the evaluation of patients with acute onset of neuropsychiatric systemic lupus erythematosus. Neuroradiology2005; 47: 576—585.
54.
Rudkin TM, Arnold DLProton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol1999; 56: 919—926.
55.
Appenzeller S. , Costallat LT, Li LM, Cendes F.Magnetic resonance spectroscopy in the evaluation of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum2006; 55: 807—811.
56.
De Certaines JD, Bovee WM, Podo F.Magnetic resonance spectroscopy in biology and medicine: functional and pathological tissue characterization. NY: Pergamon Press; 1992.
